A Phase 4 interventional study of Risankizumab and Apremilast in Psoriasis, sponsored by AbbVie. Completed at 54 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 7th largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 4, and was the 26th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 352 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 12th largest by enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2021, is one of 5 in phase 4, and was the 70th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored.
Risankizumab (Skyrizi) and apremilast are approved drugs for the treatment of moderate to severe PsO. Approximately 330 participants with moderate plaque psoriasis (PsO) will be enrolled across approximately 55 sites globally.
The study has 2 periods : Period A from Baseline to Week 16, and Period B, from Week 16 to Week 52. In Period A, participants will be randomly placed into 2 groups to receive either subcutaneous risankizumab or oral apremilast for 16 weeks. In Period B, participants who received apremilast in Period A will again be randomly assigned to 1 of the 2 groups to receive either risankizumab or apremilast for 36 weeks. At weeks 28 and 40, participants considered non-responders to apremilast based on their psoriasis score will be offered to receive risankizumab.
There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B).
Drug: Risankizumab
Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication.
Drug: Risankizumab · Drug: Apremilast
Subcutaneous injection
Also known as: ABBV-066, Skyrizi
Oral Tablets
Also known as: Otezla
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
Time frame: Week 16
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A)
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).
Time frame: Week 16
Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
Time frame: Week 16
Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR)
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).
Time frame: Week 52
A total of 352 participants were enrolled from 48 sites across 5 countries including Canada, Germany, Israel, Poland, and the United States.
| Milestone | Period A: APR | Periods A/B: RZB/RZB | Period B: APR/APR, NR | Period B: APR/RZB, NR | Period B: APR/APR, R | Period B: APR/RZB, R |
|---|---|---|---|---|---|---|
| Started | 234 | 118 | 0 | 0 | 0 | 0 |
| Completed | 216 | 118 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 6 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Period A: APR | Periods A/B: RZB/RZB | Period B: APR/APR, NR | Period B: APR/RZB, NR | Period B: APR/APR, R | Period B: APR/RZB, R |
|---|---|---|---|---|---|---|
| Started | 0 | 118 | 78 | 83 | 22 | 20 |
| Received ≥ 1 dose of study drug | 0 | 116 | 75 | 82 | 22 | 20 |
| Received rzb as rescue medication | 0 | 0 | 47 | 0 | 1 | 0 |
| Completed | 0 | 69 | 42 | 57 | 15 | 13 |
| Not completed | 0 | 49 | 36 | 26 | 7 | 7 |
| Withdrew: Lost to follow-up | 0 | 6 | 4 | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 13 | 2 | 3 | 0 |
| Withdrew: Other, not specified | 0 | 38 | 19 | 18 | 4 | 7 |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Period A: APR | Period A: RZB |
|---|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A) | 5.1 (2.3 to 8.0) | 55.9 (47.0 to 64.9) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).
| percentage of participants | Period A: APR | Period A: RZB |
|---|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population at Week 16 (ITT_A) | 18.4 (13.4 to 23.3) | 75.4 (67.7 to 83.2) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Period B: APR/APR, NR | Period B: APR/RZB, NR |
|---|---|---|
| Percentage of Participants Achieving PASI 90 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR) | 2.6 (0.0 to 6.1) | 72.3 (62.7 to 81.9) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Period A: APR | Period A: RZB |
|---|---|---|
| Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A) | 18.8 (13.8 to 23.8) | 84.7 (78.3 to 91.2) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Period B: APR/APR, NR | Period B: APR/RZB, NR |
|---|---|---|
| Percentage of Participants Achieving PASI 75 in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR) | 11.5 (4.4 to 18.6) | 83.1 (75.1 to 91.2) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).
| percentage of participants | Period B: APR/APR, NR | Period B: APR/RZB, NR |
|---|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) 0 or 1 With at Least 2-grade Improvement From Baseline in Intent to Treat Population for Apremilast Non-Responders at Week 52 (ITT_B_NR) | 7.7 (1.8 to 13.6) | 77.1 (68.1 to 86.1) |
Collected over All Cause Mortality: From enrollment up to end of study, for an overall median of 419.5 days. Adverse Events: From first dose of study drug through approximately 20 weeks (140 days) after administration of the last dose of RZB (i.e., Week 40 for participants originally randomized to RZB and Week 44 for participants switched from APR to RZB) or approximately 4 weeks (28 days) after the last dose of APR (i.e., Week 56 for participants who remain on the APR arm after re-randomization).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period A: APR | 0/234 (0%) | 4/234 (1.7%) | 101/234 (43.2%) |
| Period A: RZB | 0/118 (0%) | 1/118 (0.8%) | 24/118 (20.3%) |
| Period B: RZB/RZB | 0/116 (0%) | 8/116 (6.9%) | 36/116 (31%) |
| Period B: APR/APR | 0/97 (0%) | 2/97 (2.1%) | 27/97 (27.8%) |
| Period B: APR/RZB | 0/102 (0%) | 3/102 (2.9%) | 31/102 (30.4%) |
| Period B: APR/APR/RZB | 0/48 (0%) | 0/48 (0%) | 15/48 (31.3%) |
| Event | Period A: APR | Period A: RZB | Period B: RZB/RZB | Period B: APR/APR | Period B: APR/RZB | Period B: APR/APR/RZB |
|---|---|---|---|---|---|---|
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/234 | 0/118 | 2/116 | 0/97 | 0/102 | 0/48 |
| CORONARY ARTERY DISEASECardiac disorders | 0/234 | 0/118 | 0/116 | 1/97 | 0/102 | 0/48 |
| PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/234 | 0/118 | 0/116 | 1/97 | 0/102 | 0/48 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/234 | 0/118 | 0/116 | 0/97 | 1/102 | 0/48 |
| HYPERSENSITIVITYImmune system disorders | 0/234 | 0/118 | 0/116 | 0/97 | 1/102 | 0/48 |
| FALLInjury, poisoning and procedural complications | 0/234 | 0/118 | 0/116 | 0/97 | 1/102 | 0/48 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 0/234 | 0/118 | 0/116 | 0/97 | 1/102 | 0/48 |
| URTICARIASkin and subcutaneous tissue disorders | 0/234 | 0/118 | 0/116 | 0/97 | 1/102 | 0/48 |
| OBSTRUCTIVE PANCREATITISGastrointestinal disorders | 0/234 | 0/118 | 1/116 | 0/97 | 0/102 | 0/48 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/234 | 0/118 | 1/116 | 0/97 | 0/102 | 0/48 |
| Event | Period A: APR | Period A: RZB | Period B: RZB/RZB | Period B: APR/APR | Period B: APR/RZB | Period B: APR/APR/RZB |
|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 47/234 | 1/118 | 0/116 | 1/97 | 1/102 | 0/48 |
| NAUSEAGastrointestinal disorders | 41/234 | 0/118 | 2/116 | 3/97 | 0/102 | 0/48 |
| COVID-19Infections and infestations | 16/234 | 13/118 | 19/116 | 14/97 | 12/102 | 6/48 |
| HEADACHENervous system disorders | 27/234 | 3/118 | 1/116 | 4/97 | 5/102 | 1/48 |
| NASOPHARYNGITISInfections and infestations | 10/234 | 4/118 | 11/116 | 8/97 | 10/102 | 5/48 |
| HYPERTENSIONVascular disorders | 3/234 | 2/118 | 6/116 | 0/97 | 1/102 | 3/48 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/234 | 3/118 | 5/116 | 3/97 | 6/102 | 1/48 |
| Age, Continuous(years) | Period A: APR | Period A: RZB | Total |
|---|---|---|---|
| Mean | 46.2 ± 14.27 | 45.5 ± 13.63 | 46.0 ± 14.04 |
| Sex: Female, Male(Participants) | Period A: APR | Period A: RZB | Total |
|---|---|---|---|
| Female | 79 | 42 | 121 |
| Male | 155 | 76 | 231 |
| Ethnicity (NIH/OMB)(Participants) | Period A: APR | Period A: RZB | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 7 | 30 |
| Not Hispanic or Latino | 211 | 111 | 322 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Period A: APR | Period A: RZB | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 14 | 12 | 26 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 9 | 5 | 14 |
| White | 209 | 98 | 307 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jun 2021 to primary completion in Apr 2023, 22 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab